Leslie Khawli

Prof. Leslie Khawli

University of Southern California
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2015 in mAbs
Verified
Journal Article
Open access
JTJay Tibbitts
Jay Tibbitts
DCDavid Canter
David Canter
RGRyan Graff
Ryan Graff
ASAlison Smith
Alison Smith
Leslie KhawliLeslie Khawli
Leslie Khawli
Protein therapeutics represent a diverse array of biologics including antibodies, fusion proteins, and therapeutic replacement enzymes. Since their inception, they have revolutionized the treatment of a wide range of diseases including respiratory, vascular, autoimmune, inflammatory, infectious, and neurodegenerative diseases, as well as cancer. While in vivo pharmacokinetic, pharmacodynamic, and efficacy studies are routinely carried out for protein therapeutics, studies that identify key factors governing their absorption, distribution, metabolism, and excretion (ADME) properties have not been fully investigated. Thorough characterization and in-depth study of their ADME properties are critical in order to support drug discovery and development processes for the production of safer and more effective biotherapeutics. In this review, we discuss the main factors affecting the ADME characteristics of these large macromolecular therapies. We also give an overview of the current tools, technologies, and approaches available to investigate key factors that influence the ADME of recombinant biotherapeutic drugs, and demonstrate how ADME studies will facilitate their future development.

10 June 2020 in Antibodies
Verified
Journal Article
Open access
PDF file
SBSouad Boune
Souad Boune
PHPeisheng Hu
Peisheng Hu
AEAlan Epstein
Alan Epstein
Leslie KhawliLeslie Khawli
Leslie Khawli
The development of recombinant therapeutic proteins has been a major revolution in modern medicine. Therapeutic-based monoclonal antibodies (mAbs) are growing rapidly, providing a potential class of human pharmaceuticals that can improve the management of cancer, autoimmune diseases, and other conditions. Most mAbs are typically of the immunoglobulin G (IgG) subclass, and they are glycosylated at the conserved asparagine position 297 (Asn-297) in the CH2 domain of the Fc region. Post-translational modifications here account for the observed high heterogeneity of glycoforms that may or not impact the stability, pharmacokinetics (PK), efficacy, and immunogenicity of mAbs. These modifications are also critical for the Fc receptor binding, and consequently, key antibody effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Moreover, mAbs produced in non-human cells express oligosaccharides that are not normally found in serum IgGs might lead to immunogenicity issues when administered to patients. This review summarizes our understanding of the terminal sugar residues, such as mannose, sialic acids, fucose, or galactose, which influence therapeutic mAbs either positively or negatively in this regard. This review also discusses mannosylation, which has significant undesirable effects on the PK of glycoproteins, causing a decreased mAbs’ half-life. Moreover, terminal galactose residues can enhance CDC activities and Fc–C1q interactions, and core fucose can decrease ADCC and Fc–FcγRs binding. To optimize the therapeutic use of mAbs, glycoengineering strategies are used to reduce glyco-heterogeneity of mAbs, increase their safety profile, and improve the therapeutic efficacy of these important reagents.

Verified
Journal Article
Open access
AKAida Kouhi
Aida Kouhi
Vyshnavi PachipulusuVyshnavi Pachipulusu
Vyshnavi Pachipulusu
TKTalya Kapenstein
Talya Kapenstein
PHPeisheng Hu
Peisheng Hu
AEAlan Epstein
Alan Epstein
Leslie KhawliLeslie Khawli
Leslie Khawli
Due to their high specificity, monoclonal antibodies have been widely investigated for their application in drug delivery to the central nervous system (CNS) for the treatment of neurological diseases such as stroke, Alzheimer’s, and Parkinson’s disease. Research in the past few decades has revealed that one of the biggest challenges in the development of antibodies for drug delivery to the CNS is the presence of blood–brain barrier (BBB), which acts to restrict drug delivery and contributes to the limited uptake (0.1–0.2% of injected dose) of circulating antibodies into the brain. This article reviews the various methods currently used for antibody delivery to the CNS at the preclinical stage of development and the underlying mechanisms of BBB penetration. It also describes efforts to improve or modulate the physicochemical and biochemical properties of antibodies (e.g., charge, Fc receptor binding affinity, and target affinity), to adapt their pharmacokinetics (PK), and to influence their distribution and disposition into the brain. Finally, a distinction is made between approaches that seek to modify BBB permeability and those that use a physiological approach or antibody engineering to increase uptake in the CNS. Although there are currently inherent difficulties in developing safe and efficacious antibodies that will cross the BBB, the future prospects of brain-targeted delivery of antibody-based agents are believed to be excellent.

8 August 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ASAlison Smith
Alison Smith
HMHugh Manoli
Hugh Manoli
SJStacey Jaw
Stacey Jaw
KFKimberley Frutoz
Kimberley Frutoz
AEAlan L. Epstein
Alan L. Epstein
FTFrank-Peter Theil
Frank-Peter Theil
Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies. Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids. Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous. Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes. Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs. Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics. We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.

21 April 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CBC. Andrew Boswell
C. Andrew Boswell
EMEduardo E. Mundo
Eduardo E. Mundo
SUSheila Ulufatu
Sheila Ulufatu
DBDaniela Bumbaca
Daniela Bumbaca
HCHendry S. Cahaya
Hendry S. Cahaya
Leslie KhawliLeslie Khawli
Leslie Khawli

15 July 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LZLong Zheng
Long Zheng
LRLuqing Ren
Luqing Ren
AKAida Kouhi
Aida Kouhi
Leslie KhawliLeslie Khawli
Leslie Khawli
PHPeisheng Hu
Peisheng Hu
AEAlan L. Epstein
Alan L. Epstein
Purpose: The murine Lym-1 monoclonal antibody targets a discontinuous epitope (Lym-1 epitope) on several subtypes of HLA-DR, which is upregulated in a majority of human B-cell lymphomas and leukemias. Unlike CD19, the Lym-1 epitope does not downregulate upon crosslinking, which may provide an advantage as a target for CAR T cell therapy. Lym-1 CAR T cells with a conventional 4-1BB and CD3z (BB3z) signaling domain exhibited impaired ex vivo expansion. This study aimed to identify the underlying mechanisms and develop strategies to overcome this effect. Experimental Design: A functional humanized Lym-1 antibody (huLym-1-B) was identified and its scFv form was used for CAR design. To overcome observed impaired expansion in vitro, a huLym-1-B CAR using DAP10 and DAP12 (DAP) signaling domains was evaluated for ex vivo expansion and in vivo function. Results: Impaired expansion in huLym-1-B-BB3z CAR T cells was shown to be due to ligand-dependent suboptimal CAR signaling caused by interaction of the CAR binding domain and the surface of human T cells. Using the novel DAP signaling domain construct, the effects of suboptimal CAR signaling were overcome to produce huLym-1-B CAR T cells with improved expansion ex vivo and function in vivo. In addition, the Lym-1 epitope does not significantly downregulate in response to huLym-1-B-DAP CAR T cells both ex vivo and in vivo. Conclusions: DAP intracellular domains can serve as signaling motifs for CAR, and this new construct enables non-impaired production of huLym-1-B CAR T cells with potent in vivo anti-tumor efficacy.